戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ast one blood pressure-lowering drug and one lipid-lowering drug.
2 tal cholesterol, antihypertensive drugs, and lipid-lowering drugs.
3 ed as proxies to study the efficacy of these lipid-lowering drugs.
4   Subgroup analyses were performed by use of lipid-lowering drugs.
5 ociations were observed regardless of use of lipid-lowering drugs.
6 ght, weight, and use of antihypertensive and lipid-lowering drugs.
7 ipidemia, nearly half of whom were receiving lipid-lowering drugs.
8 ein cholesterol (LDL-c) >/=130 mg/dL, and no lipid-lowering drugs.
9 isk factors, and use of antihypertensive and lipid-lowering drugs.
10 ia and often require treatment with multiple lipid-lowering drugs.
11 d by risk and recommendations for the use of lipid-lowering drugs.
12 y revascularization and 70 percent receiving lipid-lowering drugs.
13 ng enzyme inhibitors, and 53% were receiving lipid-lowering drugs.
14 nfluences the lipid and clinical response to lipid-lowering drugs.
15 chronic disease score, and use of non-statin lipid-lowering drugs.
16 osis of hyperlipidaemia or exposure to other lipid-lowering drugs.
17  between fracture risk and use of non-statin lipid-lowering drugs.
18 be a potential target for the development of lipid-lowering drugs.
19 y intake, diabetes, hypertension, and use of lipid-lowering drugs.
20  decided to use one, should we add the other lipid-lowering drug?
21                                          The lipid-lowering drugs, 3-hydroxy-3-methylgulutaryl-coenzy
22 ents: 49% (7,836/16,028) were not prescribed lipid-lowering drugs, 52% (1,647/3,194) were not prescri
23 sin II receptor blockers, beta-blockers, and lipid-lowering drugs also increased among both sexes.
24  cell DNA from 991 Whites in the Genetics of Lipid Lowering Drugs and Diet Network Study was followed
25  nondiabetic participants in the Genetics of Lipid Lowering Drugs and Diet Network study, divided int
26                    In the GOLDN (Genetics of Lipid Lowering Drugs and Diet Network) study, higher ABC
27 bolic diseases in 3 populations (Genetics of Lipid Lowering Drugs and Diet Network, n = 978; Framingh
28 dchip in 991 participants of the Genetics of Lipid Lowering Drugs and Diet Network.
29                                 Fibrates are lipid lowering drugs and found as ligands for peroxisome
30                 Fenofibrate (FF) is a common lipid-lowering drug and a potent agonist of the peroxiso
31  underlines the importance of gemfibrozil, a lipid-lowering drug and an activator of peroxisome proli
32                    Preventive drugs, such as lipid-lowering drugs and antidiabetic drugs, have additi
33 rage drug-gene databases to identify several lipid-lowering drugs and antioxidants with high potentia
34 s, (3) assess additive effects with approved lipid-lowering drugs, and (4) identify secondary indicat
35 ngiotensin-converting enzyme inhibitors, and lipid-lowering drugs, and smoking cessation counseling f
36 ity assessment of conduit and target vessel, lipid-lowering drugs, antithrombotic therapy, and cessat
37 r-activated receptor alpha (PPARalpha) and a lipid-lowering drug approved by the Food and Drug Admini
38                                              Lipid-lowering drugs are associated with myotoxicity, wh
39                Statins, the most widely used lipid-lowering drugs, are increasingly recognized to hav
40                            Prescription of a lipid-lowering drug at hospital discharge was independen
41 luation of risk factors prior to prescribing lipid-lowering drugs, attention to muscle symptoms, and
42 or are intolerant to statins, should another lipid-lowering drug be added, either a proprotein conver
43 substantial increase in antihypertensive and lipid-lowering drugs, blood pressure management remained
44 artiles of suPAR, including age, sex, use of lipid-lowering drugs, body mass index, diabetes mellitus
45 mination increased physician prescription of lipid-lowering drugs but not antihypertensive drugs with
46                S1P is a potential target for lipid-lowering drugs, but the effect of S1P blockade in
47 C1L1 did not suggest that the use of related lipid-lowering drug classes would affect AD risk.
48 code the protein targets of several approved lipid-lowering drug classes: HMGCR (encoding the target
49            Consequently, the total dosage of lipid-lowering drug consumed, the concomitant use of oth
50 e that oral administration of gemfibrozil, a lipid-lowering drug, decreases glial inflammation, norma
51    The proportions of BMI categories, use of lipid-lowering drugs, diabetes and/or use of antidiabeti
52      Recommendations for the prescription of lipid-lowering drugs emphasise the importance of an asse
53 cle was to evaluate the relationship between lipid-lowering drug exposure time and relative risk redu
54                 By activating PPARalpha, the lipid-lowering drug fenofibrate reverses dyslipidemia an
55                                        Also, lipid-lowering drugs fenofibrate and niacin reduced live
56 cetamide (BPA) structure present in a common lipid-lowering drug, fenofibrate, and in our first proto
57  based on the chemical structure of a common lipid-lowering drug, fenofibrate, and share a general mo
58 ammatory effect of gemfibrozil, a prescribed lipid-lowering drug for humans, in mouse microglia.
59 s, patients failed to fill prescriptions for lipid-lowering drugs for about 40% of the study year.
60 inhibitors) are the most prescribed class of lipid-lowering drugs for the treatment and prevention of
61 ies that may allow personalized selection of lipid-lowering drugs for those at risk of psoriasis.
62 ward, and a prospective analysis for general lipid-lowering drugs from 1994 to 2004.
63               Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is i
64  of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease dr
65 led and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease dr
66 rlier studies have shown that gemfibrozil, a lipid-lowering drug, has anti-inflammatory properties.
67  statins, the panel suggests adding a second lipid-lowering drug in people at very high and high card
68 ant to statins, the panel recommends using a lipid-lowering drug in people at very high and high card
69 rated PPARalpha agonists beyond their use as lipid-lowering drugs in anticancer therapy.
70               CETP inhibitors are a class of lipid-lowering drugs in development for treatment of cor
71 em), a Food and Drug Administration-approved lipid-lowering drug, in increasing the expression of IL-
72 zil, a Food and Drug Administration-approved lipid-lowering drug, in up-regulating the expression of
73 brate, Food and Drug Administration-approved lipid-lowering drugs, in up-regulating TPP1 in brain cel
74 by factors that elevate tissue levels of the lipid-lowering drug, including the dose, drug-drug inter
75 ention drug clinically indicated: 16,028 had lipid-lowering drugs indicated, 3,194 anticoagulant drug
76                               Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced producti
77 ncomitant treatment of lomitapide with other lipid-lowering drugs is generally safe.
78 zil, a Food and Drug Administration-approved lipid-lowering drug, is known to decrease the risk of co
79                                     Both the lipid-lowering drug lovastatin and the Rac1-specific inh
80                                              Lipid-lowering drugs may be indicated in this subgroup.
81            A few studies have suggested that lipid-lowering drugs may have anti-arrhythmic effects in
82 d suggests that simvastatin, an FDA-approved lipid-lowering drug, may benefit to prevent the pathogen
83 d suggests that simvastatin, an FDA-approved lipid-lowering drug, may help prevent the pathogenesis a
84                        Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (P
85 nsives (n = 5), oral antidiabetics (n = 12), lipid-lowering drugs (n = 7), antiplatelets (n = 2).
86     In this study, we examined the impact of lipid-lowering drugs of the statin family on YAP localiz
87 nded therapies, including smoking cessation, lipid lowering drugs, optimal glucose control, and antit
88 tained in analyses excluding subjects taking lipid-lowering drugs or estrogen and in analyses adjuste
89 tment on American Heart Association diet and lipid-lowering drugs or on strict low-fat diet (<10% of
90 re not using an antihypertensive medication, lipid-lowering drugs, or a glucose-lowering treatment.
91 dds ratio [OR], 1.60 [95% CI, 1.50 to 1.71]; lipid-lowering drugs: OR, 1.59 [CI, 1.50 to 1.68]).
92  likely to be taking aspirin (P < 0.001) and lipid-lowering drugs (P = 0.006).
93 0-95 mg/dL)] who were not being treated with lipid-lowering drugs participated.
94 d a decrease in monthly antihypertensive and lipid-lowering drug prescriptions during the coverage ga
95           Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the tr
96 ations studied, patients who were prescribed lipid-lowering drug regimens remained without filled pre
97 ntihypertensives, antithrombotic agents, and lipid-lowering drugs (relative risk, 0.55 [95% confidenc
98                                          The lipid-lowering drug simvastatin decreases portal pressur
99 hysicians are increasingly considering other lipid-lowering drugs solely for achieving LDL cholestero
100                               In addition to lipid-lowering drugs - statins, dietary control, and exe
101       Here, we delineate that gemfibrozil, a lipid-lowering drug, stimulates GDNF in astrocytes via p
102 d in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized
103                        As IDOL is a putative lipid-lowering drug target, we investigated the molecula
104 iants indexed expected effects of modulating lipid-lowering drug targets on PD.
105 ring on PAD risk using gene regions proxying lipid-lowering drug targets.
106                 Berberine (BBR) is a natural lipid lowering drug that reduces plasma LDL-cholesterol
107 eated for 6 weeks with either bezafibrate, a lipid-lowering drug that does not affect plasma glucose
108                       Statins are one of the lipid-lowering drugs that help in reducing cholesterol l
109                 When choosing to add another lipid-lowering drug, the panel suggests ezetimibe in pre
110                  Among potential agents, the lipid-lowering drugs, the statins, satisfy these prerequ
111 d inflammation and the potential benefits of lipid-lowering drug therapy after heart transplantation.
112 have negative effects on adherence to statin lipid-lowering drug therapy but not on their initiation
113 th advanced atherosclerosis, NCEP recommends lipid-lowering drug therapy if LDL cholesterol remains >
114 e sufficiently frequent during the course of lipid-lowering drug therapy to pose diagnostic challenge
115 .3% (1964/6704) had dyslipidemia, among whom lipid-lowering drug therapy was reported by 54.0% (1060/
116 thin a single family, and more responsive to lipid-lowering drug therapy.
117 rol (LDL-C) levels to assess eligibility for lipid-lowering drug therapy.
118 olesterolemic patients who are refractory to lipid-lowering drug therapy.
119 fication, in particular early and aggressive lipid-lowering drug therapy; and a number of evolving th
120 uals, 19.7% of those who did not qualify for lipid-lowering drug treatment had CAC >400.
121 characterized regarding plasma lipid status, lipid-lowering drug treatment, and variants at the LPA g
122 periments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibra
123 the incidence of diabetes, hypertension, and lipid-lowering drug use after 144 weeks.
124                                              Lipid-lowering drug use rose significantly for both sexe
125 ased incidence of diabetes, hypertension, or lipid-lowering drug use was observed after the follow-up
126 trends in cholesterol, hypercholesterolemia, lipid-lowering drug use, and cholesterol awareness, trea
127                       First prescriptions of lipid-lowering drugs were higher in the intervention gro
128 iving patients who were initially prescribed lipid-lowering drugs were still filling prescriptions fo
129 ds are promising alternatives to the current lipid-lowering drugs, which cause many undesirable effec
130 atherosclerosis in subjects not treated with lipid-lowering drugs while the process is still confined
131 nt of glioblastoma cells with fenofibrate, a lipid-lowering drug with multiple anticancer activities.
132                      Most studies compared a lipid-lowering drug with placebo but did not evaluate th
133                      Statins are widely used lipid-lowering drugs with immunomodulatory properties th
134 res of prescriptions of antihypertensive and lipid-lowering drugs within 465 days after ultrasonograp

 
Page Top